Similarly, in SLE mouse models, PD-1 blockade can activate suppressive CD8+ T cells, thereby delaying the onset of renal disease and the progression of SLE, ultimately leading to an increase in the survival rates of the mice [53]. The gene discussed is CD8A; the disease is systemic lupus erythematosus.